Chest
-
Randomized Controlled Trial Clinical Trial
Pharmacoeconomic evaluation of a combination of ipratropium plus albuterol compared with ipratropium alone and albuterol alone in COPD.
To conduct a post hoc pharmacoeconomic evaluation of two double-blind, randomized, prospective, parallel group studies comparing the long-term efficacy and safety of ipratropium combined with albuterol in a single inhalational canister against either bronchodilator agent alone in patients with COPD. ⋯ The inclusion of ipratropium in a pharmacologic treatment regimen is associated with a lower rate of exacerbations in COPD. The result is lower total treatment costs and improved cost-effectiveness.
-
Randomized Controlled Trial Multicenter Study Clinical Trial
Nocturnal asthma: effect of salmeterol on quality of life and clinical outcomes.
To evaluate the effect of salmeterol on asthma-specific quality of life in patients experiencing significant nocturnal symptoms. ⋯ These results provide evidence that validates the role of salmeterol in improving quality of life in patients with moderate persistent asthma who exhibited nocturnal asthma symptoms and supports the efficacy of salmeterol compared with that of placebo (ie, "as-needed" albuterol).